Condition: Chronic Kidney Diseases · Renal Failure · Sponsor: Hamilton Health Sciences Corporation
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
This description comes directly from the study's public registry record.
Courtney Christou, BSc · 905-521-2100 · courtney.christou@phri.ca
Jessica Tyrwhitt, BSc · jessica.tyrwhitt@phri.ca
Always discuss trial participation with your own doctor first.
| University of Alberta Hospital | Edmonton, Alberta, Canada | Not Yet Recruiting |
| St. Joseph's Healthcare Hamilton | Hamilton, Ontario, Canada | Recruiting |
| London Health Sciences Centre | London, Ontario, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06203977